01—Abstract
Summary
Summary of the 8-K filed October 21, 2026. Cited figures are marked; the original filing is the authoritative source.
Cencora, Inc. (COR) announced a significant strategic move via an 8-K filing on October 21, 2026, revealing its definitive agreement to acquire American Oncology Network, Inc. (AON) for an enterprise value of $2.4 billiona.
This acquisition is poised to bolster Cencora's position in supporting community oncology by integrating AON's physician-led network, which spans over 350 providers across 21 states, into Cencora's existing MSO platform. The company also updated its fiscal year 2026 financial expectations, projecting adjusted diluted earnings per share (EPS) to be at least $17.90b, aligning with the higher end of its previous guidance.
This updated outlook reflects the strong performance in Cencora's U.S. Healthcare Solutions segment. The acquisition of AON is anticipated to be accretive to Cencora's adjusted diluted EPS in the second year post-closing, signaling a long-term value creation strategy.
02—Key points
Key Highlights
- Cencora to acquire American Oncology Network (AON) for $2.4 billion enterprise value, comprising $2.3 billion at closing and up to $100 million in contingent value rights (CVRs).
- The acquisition aims to expand Cencora's physician-led oncology MSO platform and enhance support for community-based cancer care.
- AON is a network of over 350 oncology providers across 21 states, complementing Cencora's existing capabilities and geographic reach.
- Cencora updated its fiscal year 2026 adjusted diluted EPS guidance to at least $17.90, reflecting strength in the U.S. Healthcare Solutions segment.
- The transaction is expected to be accretive to Cencora's adjusted diluted EPS in the second year following closing.
- The deal is subject to customary closing conditions, including regulatory approvals and AON stockholder approval.
03—Questions
Frequently Asked Questions
What is the primary strategic rationale behind Cencora's acquisition of American Oncology Network?
The primary strategic rationale is to strengthen Cencora's support for community oncology by integrating AON's established physician-led network. This acquisition aims to expand Cencora's MSO platform, enhance capabilities for independent oncology practices, and improve patient access to high-quality, cost-effective cancer care.
What is the total value of the transaction, and how will it be financed?
The transaction has an enterprise value of $2.4 billion, which includes $2.3 billion at closing and up to $100 million in contingent value rights (CVRs). Cencora expects to pay approximately $1.7 billion in cash at closing, assuming certain AON stockholders participate in an equity rollover of up to 25% of AON.
Has Cencora provided any updated financial guidance for fiscal year 2026?
Yes, Cencora has updated its fiscal year 2026 financial guidance. The company now expects adjusted diluted earnings per share (EPS) to be at least $17.90, which is at the high end of its previous guidance range. This update reflects the strong performance of its U.S. Healthcare Solutions segment.
When does Cencora expect the acquisition of AON to be completed?
The filing does not provide a specific closing date, but states the transaction is subject to customary closing conditions, including the satisfaction of required regulatory clearances and AON stockholder approvals. Cencora expects to discuss its fiscal year 2027 expectations on its fourth quarter fiscal 2026 earnings call on November 4, 2026.
04—Continue